GAMMA Investing
LUCD icon

GAMMA Investing’s Lucid Diagnostics LUCD Stock Holding History

GAMMA Investing’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$351 Buy
467
+325
+229% +$304 ﹤0.01% 4235
2026
Q2 		$152 Sell
142
-752
-84% -$811 ﹤0.01% 4103
2026
Q1 		$1.03K Buy
894
+752
+530% +$957 ﹤0.01% 3833
2025
Q4 		$155 Buy
+142
New +$159 ﹤0.01% 4025

Other funds holding LUCD

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return
Sax Wealth Advisors
Sax Wealth Advisors Parsippany, New Jersey $3.5B AUM 13.73% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's LUCD Position: Q3 2026 in Review

GAMMA Investing increased its Lucid Diagnostics (LUCD) stake by 229% in Q3 2026, buying an estimated $304 and bringing the position to 467 shares worth $351. The position accounts for ﹤0.01% of the portfolio, ranked #4235.

GAMMA Investing first reported a position in LUCD in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.03K in Q1 2026. 10 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • GAMMA Investing held 467 shares of Lucid Diagnostics worth $351 as of Q3 2026.
  • GAMMA Investing bought 325 Lucid Diagnostics shares in Q3 2026, an estimated $304.
  • Lucid Diagnostics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4235 holding.
  • GAMMA Investing first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 4 quarters since.
  • GAMMA Investing's Lucid Diagnostics position peaked at $1.03K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.